Imatinib (Glivec ®) induces major cytogenetic responses in the vast majority of newly diagnosed CML patients. Most of these responses are durable, but a minority of patients progress to accelerated ...

While early, study results presented at ASH show Tern’s drug could surpass Novartis’ Scemblix and “raise the bar in efficacy” ...

Doctors use molecular responses to monitor the effectiveness of CML treatment. A major molecular response is when the amount of the abnormal BCR–ABL gene in your blood and bone marrow is lowered to ...

Enliven Therapeutics' ELVN-001 shows promising interim data, achieving a 44% major molecular response rate in heavily pre-treated CML patients within 12 weeks. ELVN-001 targets the BCR-ABL gene fusion ...

Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for ...

Tomasz Sacha, Magdalena Zawada, Sylwia Czekalska, Izabela Florek, Martin Mueller, Michał Gniot, Bożena Jaźwiec, Sławomira Kyrcz-Krzemień, Aleksandra Leszczyńska ...

Chronic myeloid leukemia may seem to appear suddenly, but new research shows it begins years before diagnosis with an explosive surge of growth. Scientists tracked how a single genetic accident—the ...

To support the validation and verification of new assays and to challenge the existing assays in oncology testing, Thermo Fisher Scientific launches Thermo Scientific Acrometrix BCR-ABL Panel. The ...

Asciminib is an allosteric inhibitor that binds a myristoyl site of the BCR-ABL1 protein, locking BCR-ABL1 into an inactive conformation through a mechanism distinct from those for all other ABL ...